CO6160302A2 - Formulaciones farmaceuticas - Google Patents

Formulaciones farmaceuticas

Info

Publication number
CO6160302A2
CO6160302A2 CO09036680A CO09036680A CO6160302A2 CO 6160302 A2 CO6160302 A2 CO 6160302A2 CO 09036680 A CO09036680 A CO 09036680A CO 09036680 A CO09036680 A CO 09036680A CO 6160302 A2 CO6160302 A2 CO 6160302A2
Authority
CO
Colombia
Prior art keywords
salt
acid
temperature
potassium phosphate
phosphate buffer
Prior art date
Application number
CO09036680A
Other languages
English (en)
Spanish (es)
Inventor
Yi Gao
R Ju Tzuchi
Hauiliang Wu
Nicole Nguyen
Dennis Lee
Original Assignee
Abbott Lab
Fournier Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, Fournier Lab Ireland Ltd filed Critical Abbott Lab
Publication of CO6160302A2 publication Critical patent/CO6160302A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CO09036680A 2006-10-12 2009-04-13 Formulaciones farmaceuticas CO6160302A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82925506P 2006-10-12 2006-10-12

Publications (1)

Publication Number Publication Date
CO6160302A2 true CO6160302A2 (es) 2010-05-20

Family

ID=38961056

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09036680A CO6160302A2 (es) 2006-10-12 2009-04-13 Formulaciones farmaceuticas

Country Status (14)

Country Link
EP (1) EP2081563A1 (zh)
JP (1) JP2010506855A (zh)
KR (1) KR20090119959A (zh)
CN (1) CN101677981A (zh)
AU (1) AU2007307641A1 (zh)
CA (1) CA2672686A1 (zh)
CO (1) CO6160302A2 (zh)
EA (1) EA200900531A1 (zh)
EC (1) ECSP099251A (zh)
IL (1) IL198160A0 (zh)
MX (1) MX2009003815A (zh)
SG (1) SG175570A1 (zh)
WO (1) WO2008046052A1 (zh)
ZA (1) ZA200902488B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0912161A2 (pt) * 2008-05-30 2015-10-06 Ucb Pharma Sa composição farmacêutica na forma de um tablete
CN102304103A (zh) * 2011-06-03 2012-01-04 郑州泰基鸿诺药物科技有限公司 一种非诺贝特酸盐、制备方法、药物组合物及应用
CN102659570B (zh) * 2012-05-17 2014-05-28 安润医药科技（苏州）有限公司 二氟非诺贝特酸及其在药学上可接受的盐，以及它们的制备方法和应用
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
CN107496397A (zh) * 2016-06-14 2017-12-22 重庆安格龙翔医药科技有限公司 一种二甲双胍与非诺贝酸的复合物及其制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1832285A1 (en) * 2002-12-17 2007-09-12 Abbott GmbH & Co. KG Formulation comprising fenofibric acid or a physiologically acceptable salt thereof
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
CN101480384A (zh) * 2002-12-17 2009-07-15 阿伯特有限及两合公司 包含非诺贝酸、其生理可接受的盐或衍生物的制剂
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
SG161256A1 (en) * 2005-04-08 2010-05-27 Abbott Lab Oral pharmaceutical formulations comprising fenofibric acid and/or its salts

Also Published As

Publication number Publication date
ECSP099251A (es) 2009-06-30
EA200900531A1 (ru) 2009-12-30
AU2007307641A1 (en) 2008-04-17
KR20090119959A (ko) 2009-11-23
JP2010506855A (ja) 2010-03-04
IL198160A0 (en) 2009-12-24
MX2009003815A (es) 2009-09-07
CN101677981A (zh) 2010-03-24
WO2008046052A1 (en) 2008-04-17
CA2672686A1 (en) 2008-04-17
EP2081563A1 (en) 2009-07-29
ZA200902488B (en) 2010-10-27
SG175570A1 (en) 2011-11-28

Similar Documents

Publication Publication Date Title
AR074347A1 (es) Composicion solida para liberacion controlada de agentes activos ionizables con solubilidad acuosa deficiente a ph bajo y sus metodos de uso
CO6150127A2 (es) Formulaciones de flibanserina y metodo para fabricarlas
ES2606342T3 (es) Composiciones para el cuidado bucal de sal estannosa y tripoli-fosfato de sodio y métodos
CO6160302A2 (es) Formulaciones farmaceuticas
RS20070511A (en) Modified release pharmaceutical compositions and processes thereof
BRPI0517916A (pt) comprimido que compreende um sal de carbonato de um polìmero de amina alifática, composições e método para remover fosfato de um paciente com necessidade do mesmo
AR062760A1 (es) Administracion de inhibidores de dipeptidilpetidasa
PE20001058A1 (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
JP2018021007A5 (zh)
AR054238A1 (es) Composicion farmaceutica que contiene una biguanida y un derivado de tiazolidindiona
NZ620887A (en) A novel formulation of diclofenac
EA201290026A1 (ru) Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
CA3019769C (en) Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
UA89684C2 (ru) Двухслойная фармацевтическая дозированная форма с модифицированным высвобождением нимесулида
CL2011001178A1 (es) Uso de (r)-7-cloro-niquinuclidin-3-1l)senzo[b]tiofen0-2-carboxamida o una sal de la misma o una composicion farmaceutica que la comprende para preparar un medicamento util para mejorar la cognicion en un paciente que sufre de alzheimer o esquizofrenia.
MEP10808A (en) Solid drug for oral use
AR095159A2 (es) Una composición farmacéutica en forma de cápsula para administración oral
CO6351716A2 (es) Formulación de liberación modificada y métodos de uso
HRP20161717T1 (hr) Nalmefen za smanjenje konzumacije alkohola u specifičnim ciljnim populacijama
CO5560554A2 (es) Composicion farmaceutica que comprende lumiracoxib
JP2015521647A5 (zh)
EA023535B9 (ru) Композиция водного радиопротекторного фармацевтического раствора и способ предотвращения, снижения или исключения эффектов ионизирующей радиации
JP2010518075A (ja) 局所的鼻腔投与のためのオロパタジンの製剤
JP2010506855A5 (zh)
AR067630A1 (es) Soluciones farmaceuticas de telbivudina y metodo de tratamiento